Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

비소세포폐암에 사용되는 항암화학요법의 요양급여기준 적절성 평가

Full metadata record
DC Field Value Language
dc.contributor.author김정연-
dc.contributor.author박은지-
dc.contributor.author배민경-
dc.contributor.author윤정현-
dc.date.accessioned2021-10-05T07:40:04Z-
dc.date.available2021-10-05T07:40:04Z-
dc.date.issued2011-09-
dc.identifier.issn1226-6051-
dc.identifier.urihttps://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/52529-
dc.description.abstractPurpose: The purpose of this study is to assess appropriateness of current standard for insurance coverage by Health Insurance Review & Assessment Service (HIRA) on chemotherapy used in the treatment of advanced non-small cell lung cancer (NSCLC), by reviewing a variety of clinical evidences, and thereby, if needed, to propose an updated evidence-based recommendations. Methods: We collected data from HIRA regarding on the insurance standard which includes the scope and conditions for coverage on systemic chemotherapy of NSCLC. We performed a search for clinical databases and examined the most current clinical evidence from clinical literature including various clinical practice guidelines. Based on the collected data the appropriateness of HIRA standard for insurance coverage of chemotherapy of NSCLC was assessed. Results: Collected data demonstrated that HIRA standard did not reflect the most current clinical practice and evidence. Some were inappropriately listed in HIRA formulary and accepted as a chemotherapy being covered by insurance,despite the lack of evidences of clinical efficacy or superiority over other chemotherapeutic agents or regimens. In addition, there seems to be a need for a modification on the standard for insurance coverage of certain newer chemotherapeutic agents based on the current accumulated data showing their clinical efficacy and benefits in the selected group of NSCLC patients. Therefore, we concluded that current HIRA standard for insurance coverage on chemotherapy of NSCLC needs to be revised and we proposed an updated recommendation based on these latest clinical evidences. Conclusion: The standard for insurance coverage of chemotherapy should be continually examined its appropriateness based on the most recent clinical evidences in a timely manner so as to provide the most effective and safe therapy to cancer patients.-
dc.format.extent15-
dc.language한국어-
dc.language.isoKOR-
dc.publisher한국임상약학회-
dc.title비소세포폐암에 사용되는 항암화학요법의 요양급여기준 적절성 평가-
dc.title.alternativeAssessment of appropriateness of standard for insurance coverage on chemotherapy used in non-small cell lung cancer (NSCLC)-
dc.typeArticle-
dc.publisher.location대한민국-
dc.identifier.bibliographicCitation한국임상약학회지, v.21, no.3, pp 193 - 207-
dc.citation.title한국임상약학회지-
dc.citation.volume21-
dc.citation.number3-
dc.citation.startPage193-
dc.citation.endPage207-
dc.identifier.kciidART001593019-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClasskci-
dc.subject.keywordAuthornon-small cell lung cancer (NSCLC)-
dc.subject.keywordAuthorHealth Insurance Review & Assessment Service (HIRA)-
dc.subject.keywordAuthorchemotherapy-
dc.subject.keywordAuthortargeted therapy-
dc.identifier.urlhttps://www.ekjcp.org/journal/view.html?uid=223&page=&sort=&scale=10&all_k=&s_t=Assessment+of+appropriateness+of+standard+for+insurance+coverage+on+chemotherapy+used+in+non-small+cell+lung+cancer&s_a=&s_k=&s_v=21&s_n=3&spage=&pn=search&year=&vmd=Full-
Files in This Item
Go to Link
Appears in
Collections
약학대학 > 약학부 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE